Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Appointed director
Inv. presentation
|
|
Altimmune, Inc. (PIP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/29/2017 |
8-K
| Form 8-K - Current report |
| 01/19/2017 |
8-K
| Acquisition/merger/asset purchase announced, Appointed a new director|
Docs:
|
"Agreement and Plan of Merger and Reorganization, by and among PharmAthene, Inc., Mustang Merger Sub, Inc., Mustang Merger Sub LLC, Altimmune, Inc. and Shareholder Representative Services LLC, as representative of Altimmune Securityholders",
"Form of PharmAthene Voting Agreement",
"Form of PharmAthene Lock-Up Agreement",
"Form of Altimmune Lock-Up Agreement",
"Phillip MacNeill Retention and Severance Agreement",
"PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases Annapolis, MD and Gaithersburg, MD, January 19, 2017 -- PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced today the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’ s current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs. The proposed transaction does not affect PharmAthene’ s previously announced special one-time cash dividend of $2.91 per share of co..." |
|
| 08/01/2013 |
8-K
| Form 8-K - Current report |
| 01/22/2007 |
8-K
| Form 8-K - Current report |
|
|